Study at a glance
How does vitamin D3 become an active hormone?
The body first converts vitamin D3 into 25-hydroxyvitamin D, a form carried in the blood and used for further activation. A later step produces calcitriol, the active hormone.
What did the liver-and-kidney cell model show?
The model produced the starting form carried in the blood. Its effects on other cells were consistent with further activation, but the final active hormone was not directly detected. Those are different levels of evidence.
What did the mouse kidney study add?
It showed that hormone signals control the final activation step in the kidney. This helps explain why more starting material does not automatically make active hormone rise by the same proportion.
Can vitamin D activation also happen outside the kidneys?
Yes. The human immune-cell experiment directly measured active vitamin D production. The amount varied with the state of the cells.
Do these studies tell people how much vitamin D to take?
No. They connect laboratory and animal evidence about this process. They do not establish a personal dose, blood target or health benefit from taking supplements.
Read the full article below ↓Vitamin D activation is often represented as a simple sequence: vitamin D3 is converted to 25-hydroxyvitamin D [25(OH)D], and 25(OH)D is then converted to the active hormone 1,25-dihydroxyvitamin D [1,25(OH)2D]. That sequence is essential, but it can conceal an important part of the physiology. Activation is not merely a chain of chemical reactions. Different tissues perform different parts of the pathway, the final activation step is subject to endocrine control, and some cells outside the kidney can generate active vitamin D locally.
The three primary studies connected here examine different parts of that architecture. One reconstructs consecutive liver-like and kidney-like metabolism in an interconnected experimental system. Another investigates how renal CYP27B1 is regulated by endocrine signals including parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23). The third directly demonstrates conversion of 25(OH)D to active 1,25(OH)2D in human macrophages outside the kidney. Read together, they help connect the basic activation sequence with the regulation and tissue specificity that determine how that sequence operates biologically.
Why vitamin D activation needs more than a two-step diagram
A two-step diagram is useful because it identifies the major chemical transformations. Vitamin D3 first undergoes 25-hydroxylation to form 25(OH)D. A further hydroxylation can then generate 1,25(OH)2D, the active hormonal form.
But the physiological meaning of those transformations depends on where they occur and how they are controlled. The first and second hydroxylation stages occupy different metabolic territories. The kidney provides an important regulated site for production of circulating 1,25(OH)2D, while selected cells outside the kidney can also express the machinery required to generate active vitamin D locally.
This means that vitamin D3, 25(OH)D and 1,25(OH)2D should not be treated as interchangeable measures of the same biological state. They occupy different positions in the pathway and are subject to different patterns of production, regulation and use.
For the parent explanation of this process, see Vitamin D Activation.
The first transition: creating the circulating precursor
The first major activation stage converts vitamin D3 into 25(OH)D. This transformation creates the principal circulating precursor from which active vitamin D can subsequently be generated.
The organ-on-chip study used for the first evidence slot provides an experimental illustration of this transition. Vitamin D3 was supplied to a connected human-cell microfluidic system containing hepatic and renal cellular compartments. LC-MS/MS directly detected 25(OH)D in the resulting eluate, demonstrating metabolic 25-hydroxylation within the experimental system.
The study is particularly useful because its architecture also attempted to model consecutive metabolism. Material leaving the hepatic cellular environment could pass downstream to the renal cellular environment rather than each metabolic stage being examined entirely in isolation.
However, the evidence boundary is important. Although 25(OH)D was directly detected, 1,25(OH)2D was not detected in the chip eluate by LC-MS/MS. Biological responses to the liver: kidney eluate were consistent with further activation, but the final metabolite was not chemically demonstrated in that experiment.
For the complete study analysis, see Hepatic and Renal Activation of Vitamin D3: Full Evidence Review.
The kidney is not simply the second stop
Once 25(OH)D is available, conversion to 1,25(OH)2D requires CYP27B1 activity. In the kidney, this step forms part of a regulated endocrine system rather than functioning as an automatic continuation of the first hydroxylation.
This distinction changes how the activation pathway should be understood. A simple diagram can make it appear that providing more precursor inevitably drives a proportional increase in active hormone. Renal physiology is more tightly controlled than that representation suggests.
The regulatory study used for the second evidence slot demonstrated this experimentally in mice. PTH stimulated renal Cyp27b1 expression, whereas FGF23 and 1,25(OH)2D provided suppressive signals. By deleting different kidney-specific genomic regulatory regions, the researchers were able to separate parts of this hormonal control machinery.
The resulting phenotypes also showed why renal activation cannot be separated from mineral homeostasis. Disrupting Cyp27b1 regulation altered not only vitamin D metabolism but also PTH, FGF23, calcium and phosphate physiology. These variables form an interacting homeostatic system rather than a set of independent switches.
For the complete study analysis, see Renal Vitamin D Activation: Full Evidence Review.
How calcium, phosphate, PTH and FGF23 fit together
Calcium and phosphate balance provides part of the physiological context in which renal vitamin D activation is regulated. PTH and FGF23 are major endocrine signals within that system, and active vitamin D itself participates in feedback regulation.
These relationships should not be collapsed into the claim that calcium, phosphate, PTH and FGF23 all regulate CYP27B1 through the same direct molecular mechanism. The experimental evidence is more differentiated. PTH, FGF23 and 1,25(OH)2D can act as endocrine regulators of renal Cyp27b1 expression, while calcium and phosphate participate in the wider homeostatic system that influences and responds to those hormonal signals.
This distinction is one reason vitamin D activation cannot be understood from vitamin D measurements alone. The active-hormone pathway interacts with mineral requirements, endocrine feedback and metabolic degradation. A change in one part of the system can provoke compensatory changes elsewhere.
Activation does not stop at the kidney
The renal pathway is central to endocrine vitamin D physiology, but CYP27B1 activity is not confined to the kidney. Selected peripheral cells and tissues can use 25(OH)D as substrate for local production of active 1,25(OH)2D.
The macrophage study used for the third evidence slot demonstrates this principle directly in a human cellular system. Human monocyte-derived macrophages supplied with 25(OH)D generated measurable 1,25(OH)2D. The active metabolite itself was detected by LC-MS/MS, providing direct evidence of extra-renal activation.
Just as importantly, the amount produced depended strongly on macrophage state. M2a macrophages generated substantially more active vitamin D than the other investigated phenotypes, while inflammatory M1 macrophages showed comparatively little metabolism of the supplied precursor.
That result introduces another layer into the activation pathway. Local availability of 25(OH)D matters, but substrate alone does not determine the metabolic outcome. The state of the cell receiving that substrate can alter how it is processed.
For the complete study analysis, see Extra-Renal Vitamin D Activation: Full Evidence Review.
Systemic activation and local activation are related but different
Renal and extra-renal production of 1,25(OH)2D should not be treated as physiologically identical simply because the same active metabolite can be produced.
Renal activation operates within a strongly regulated endocrine system and contributes importantly to circulating active-hormone physiology. Extra-renal activation can instead occur within particular cellular environments, where locally available precursor and the metabolic state of the cell can influence active-vitamin-D production.
This distinction helps explain why the concentration of one vitamin D metabolite cannot describe every layer of vitamin D physiology. Circulating precursor availability, renal endocrine activation and local cellular metabolism represent connected but non-identical biological territories.
For the broader tissue-specific framework, see Tissue-Specific Vitamin D Metabolism.
Activation is balanced by inactivation
Production of active vitamin D is only one side of the metabolic system. Cells also possess mechanisms that limit or redirect vitamin D metabolite activity. CYP24A1 participates in hydroxylation pathways associated with degradation of both 25(OH)D and 1,25(OH)2D.
This means that biological activity depends not simply on how much active metabolite can be produced, but on the balance between substrate availability, activation and inactivation. Regulation of CYP27B1 therefore has to be interpreted alongside regulation of CYP24A1 and other aspects of cellular vitamin D metabolism.
The macrophage evidence illustrates this particularly well because activation occurred alongside other metabolic routes. Different cellular states changed the balance among active-vitamin-D production, 24-hydroxylation and other metabolic products.
For the enzyme pathways governing activation and degradation, see Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).
From organ-level pathway to cellular metabolism
The conventional liver: kidney pathway remains an essential framework, but the evidence becomes more informative when organ-level metabolism is connected with what individual cells are capable of doing.
At the organ level, vitamin D3 is transformed into a circulating hydroxylated precursor and renal metabolism provides regulated production of active hormone. At the cellular level, expression and activity of metabolic enzymes determine whether available substrate is activated, degraded or processed through other pathways.
The result is a layered model rather than a single conveyor belt. Vitamin D3 enters a metabolic system; 25(OH)D provides a circulating substrate pool; renal endocrine regulation controls an important source of active hormone; and selected peripheral cells can perform additional local metabolism according to their own biological context.
For the cellular-level framework, see Vitamin D Metabolism at the Cellular Level.
What the three studies establish together
No single one of these studies establishes the complete human vitamin D activation system. They use different experimental designs and answer different questions. Their value lies in how the evidence fits together without requiring the boundaries between those studies to be erased.
The liver: kidney organ-on-chip study directly demonstrates formation of 25(OH)D and provides functional evidence consistent with consecutive hepatic and renal processing, while stopping short of direct detection of the final active metabolite. The renal regulatory study demonstrates in vivo that the final activation machinery is under differentiated endocrine control and integrated with mineral homeostasis. The macrophage study directly demonstrates that human cells outside the kidney can convert 25(OH)D into measurable active 1,25(OH)2D.
Together, these findings support a more complete interpretation of activation: vitamin D3 is metabolically transformed rather than acting as the final hormone; the availability of precursor does not alone determine active-hormone production; renal activation is regulated within an endocrine feedback system; and local extra-renal activation can vary according to cellular context.
The key physiological distinction
The most useful way to connect these layers is to distinguish conversion, regulation and location.
Conversion describes the chemical movement from vitamin D3 through hydroxylated metabolites towards active 1,25(OH)2D. Regulation describes the mechanisms that increase, suppress or redirect those conversions. Location describes the organs, tissues and cells in which particular metabolic steps occur.
These dimensions interact, but they are not interchangeable. Knowing that a cell possesses CYP27B1 does not by itself establish how much active vitamin D it produces. Knowing that 25(OH)D is available does not establish the rate of its conversion. And knowing the circulating concentration of a metabolite does not automatically reveal the metabolic conditions inside every peripheral tissue.
That is why vitamin D activation is better understood as a regulated, distributed metabolic system than as a two-arrow diagram, even though the two major hydroxylation steps remain the essential backbone of the pathway.
Putting the activation pathway together
Vitamin D3 begins the pathway as a precursor. Formation of 25(OH)D creates the major circulating substrate for subsequent activation. In the kidney, CYP27B1-mediated production of 1,25(OH)2D is integrated with endocrine signals including PTH, FGF23 and feedback from active vitamin D itself, within the wider physiology of calcium and phosphate homeostasis.
Outside the kidney, selected cells can also use 25(OH)D to generate active vitamin D locally. The macrophage evidence shows that this capacity can change dramatically with cellular state. At the same time, degradation and alternative metabolic pathways help determine how much substrate and active metabolite remain available.
The resulting picture is therefore neither purely endocrine nor purely local. Vitamin D activation connects organ-level metabolism, hormonal regulation and tissue-specific cellular processing. Understanding those connections is what turns the familiar conversion pathway into a physiological system.
Return to the parent physiology page: Vitamin D Activation.
Related reading
A New Look at the Most Successful Prodrugs for Active Vitamin D (D Hormone): Alfacalcidol and Doxercalciferol
Alfacalcidol (1α-hydroxyvitamin D3) has been widely used since 1981 as a prodrug for calcitriol (1α,25-dihydroxyvitamin D3) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis.
Original paper ↗Read more →Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients.
Original paper ↗Read more →Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23
This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
A randomized, controlled open-label study was undertaken in 60 HD patients with serum iPTH > 1000 pg/mL or persistently high iPTH ≥ 600 pg/mL even after >3 months of calcitriol (3 μg/week).
Original paper ↗Read more →Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia
Hypercalcemic hyperparathyroidism has been associated with poor outcomes after kidney transplantation (KTx).
Original paper ↗Read more →Gender specific association of parathyroid hormone and vitamin D with metabolic syndrome in population with preserved renal function
The association of parathyroid hormone (PTH) and vitamin D with Metabolic syndrome (MetS) was evaluated using representative data from the Korean population.
Original paper ↗Read more →Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years
Chronic kidney disease (CKD) is a prevalent pathological condition worldwide.
Original paper ↗Read more →Prognosis comparison in chronic kidney disease stages 4 to 5 patients with low parathyroid hormone level due to different causes
This study examines prognostic implications of PTH reduction from different etiologies.
Original paper ↗Read more →Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce.
Original paper ↗Read more →Tubular functional capacity and maladaptive parathyroid hormone response in early-stage chronic kidney disease
TFC was evaluated by measuring effective renal plasma flow (mERPF, mL/min/1.73m2) using (131I) Hippurate (131I-H) clearance, while GFR was measured using (99m) Tc-DTPA (mGFR, mL/min/1.73m2).
Original paper ↗Read more →Vitamin D Status among Thai School Children and the Association with 1,25-Dihydroxyvitamin D and Parathyroid Hormone Levels
Only 4% (21 of 529) participants had a serum 25(OH)D level below 50 nmol/L.
Original paper ↗Read more →Hepatic and Renal Activation of Vitamin D3: Study Summary
Concise study summary of experimental liver and kidney vitamin D3 metabolism, including direct 25(OH)D detection and the evidence limits for final activation.
Read more →Relationship Between Total 25-Hydroxyvitamin D and Parathyroid Hormone Concentrations During Early Gestation in Indian Women
The inverse relationship between 25(OH)D and parathyroid hormone (PTH) concentrations was examined to define the breakpoint at which PTH was maximally suppressed using a segmented regression analysis.
Original paper ↗Read more →Serum 25-hydroxyvitamin D and parathyroid hormone in relation to plasma B-type natriuretic peptide: the Hoorn Study
Therefore, we investigated whether lower 25-hydroxyvitamin D (25(OH)D) and higher PTH are cross sectionally and after 8 years of follow-up associated with higher B-type natriuretic peptide (BNP) levels in older men and women.
Original paper ↗Read more →Serum Parathyroid Hormone, 25-Hydroxyvitamin D, and Risk of Alzheimer’s Disease: A Mendelian Randomization Study
We conducted Mendelian randomization analyses to investigate the associations of serum parathyroid hormone (S-PTH) and serum 25-hydroxyvitamin D (S-25OHD) concentrations with Alzheimer’s disease (AD).
Original paper ↗Read more →The Role of Calcium, 25-Hydroxyvitamin D, and Parathyroid Hormone in Irritable Bowel Syndrome: A Bidirectional Two-Sample Mendelian Randomization Study
Therefore, we aimed to explore the bidirectional causal effects among serum calcium, Vit-D, PTH, and IBS at the genetic level by a two-sample Mendelian randomization (MR) analysis of the datasets from IEU OpenGWAS database.
Original paper ↗Read more →Three-year follow-up of serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in nursing home residents who had received 12 months of daily bread fortification with 125 μg of vitamin D3
We conducted a single-arm clinical trial in institutionalized seniors, on the effects of high-dose vitamin D3-fortified bread daily intake (clinicaltrials.gov registration NCT00789503).
Original paper ↗Read more →Threshold of 25(OH)D and consequently adjusted parathyroid hormone reference intervals: data mining for relationship between vitamin D and parathyroid hormone
By recruiting reference population, we aimed to (1): estimate the 25(OH)D threshold that maximally inhibits the PTH, which can be defined as the cutoff value for vitamin D sufficiency; (2) establish the PTH reference interval (RI) in population with sufficient vitamin D.
Original paper ↗Read more →Understanding Vitamin D3
An introduction to understanding vitamin D3: how it is absorbed, activated, regulated, interacts with other nutrients, and why individual biology and timing matter more than dose alone.
Read more →